Evidence map›Paper›PMID 34126617›Full record

Observational studyBlood purification2022

Extracorporeal Blood Purification in Moderate and Severe COVID-19 Patients: A Prospective Cohort Study.

Rodney Alexander Rosalia, Petar Ugurov, Dashurie Neziri, Simona Despotovska, Emilija Kostoska, Lidija Veljanovska-Kiridjievska, Dimche Kuzmanov, Aleksandar Trifunovski, Dijana Popevski, Gianluca Villa and 1 more

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Blood purification, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Apheresis and COVID-19 in intensive care unit (ICU).Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022
    Article
  15. Review
  16. Review
  17. COVID-19 and Acute Kidney Injury.Critical care clinics · 2022
    Review
  18. Article
  19. Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Rodney Alexander RosaliaZan Mitrev Clinic, Skopje, North Macedonia.
Petar UgurovZan Mitrev Clinic, Skopje, North Macedonia.
Dashurie NeziriZan Mitrev Clinic, Skopje, North Macedonia.
Simona DespotovskaZan Mitrev Clinic, Skopje, North Macedonia.
Emilija KostoskaZan Mitrev Clinic, Skopje, North Macedonia.
Lidija Veljanovska-KiridjievskaZan Mitrev Clinic, Skopje, North Macedonia.
Dimche KuzmanovZan Mitrev Clinic, Skopje, North Macedonia.
Aleksandar TrifunovskiDistant Point, Skopje, North Macedonia.
Dijana PopevskiZan Mitrev Clinic, Skopje, North Macedonia.
Gianluca VillaDepartment of Health Sciences, Section of Anaesthesiology, Intensive Care and Pain Medicine, University of Florence, Florence, Italy.
Zan MitrevZan Mitrev Clinic, Skopje, North Macedonia.
PHI University Psychiatric Clinic - Skopje · MKUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCoronavirus disease 2019 (COVID-19) is characterized by hyperinflammation and coagulopathy. Severe cases often develop respiratory distress, requiring mechanical ventilation and with critical cases progressing to acute respiratory distress syndrome. Control of hyperinflammation has been proposed as a possible therapeutic avenue for COVID-19; extracorporeal blood purification (EBP) modalities offer an attractive mean to ameliorate maladaptive inflammation. With this work, we evaluated the longitudinal changes of systemic inflammatory markers in critically ill COVID-19 patients treated with blood purification using AN69ST (oXiris®) haemofilter.

methodsWe performed a time-series analysis of 44 consecutive COVID-19 cases treated with the AN69ST (oXiris®) cytokine adsorbing haemofilter (CAH) according to local practice; we visualize longitudinal results of biochemical, inflammatory, blood gas, and vital sign parameters focussing on systemic levels of interleukin-6 (IL-6), C-reactive protein (CRP), and procalcitonin.

resultsAll patients were treated with ≥1 cycle extracorporeal continuous venovenous haemofiltration (CVVH) with CAH; of these, 30 severe patients received CVVH-CAH within 4-12 h of admission after recognizing a hyper-inflammatory state. Another 14 patients admitted with mild-to-moderate symptoms progressed to severe disease and were placed on EBP during hospitalization. The treatment was associated with a reduction of ferritin, CRP, fibrinogen, several inflammatory markers, and a resolution of numerous cytopenias. The observed mortality across the cohort was 36.3%.

conclusionEBP with CAH was associated with a decrease in CRP, and control of IL-6 and procalcitonin.

Indexed as

COVID-19HemofiltrationAdultAgedC-Reactive ProteinFemaleHumansInterleukin-6MaleMiddle AgedPatient AcuityProcalcitoninProspective StudiesSARS-CoV-2C-Reactive ProteinIL6 protein, humanInterleukin-6ProcalcitoninAnticoagulationCoronavirusCoronavirus disease 2019HeparinInterleukin-6oXiris

Identifiers

PMID34126617
PMCPMC8339014
OpenAlexW3171953792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.